Korean J Dermatol.  2012 Sep;50(9):810-813.

A Case of Pustular Psoriasis Developed during Infliximab Treatment for Crohn's Disease

Affiliations
  • 1Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. khcho@snu.ac.kr

Abstract

Infliximab is a monoclonal antibody that binds and inactivates tumor necrosis factor-alpha. It has been successfully used to manage diseases associated with a Th1 profile such as psoriasis, Crohn's disease, and rheumatoid arthritis. A 15-year-old boy presented for erythematous scaly papules and pustules with crust on his entire body, which had appeared initially 2 months ago. He had been treated with infliximab for Crohn's disease during the last 14 months and had not been diagnosed with psoriasis. A skin biopsy specimen demonstrated papulosquamous dermatitis with subcorneal pustule formation, suggestive of pustular psoriasis. The patient was treated with oral retinoid 20 mg/d for 3 weeks and 10 mg/d for next 3 weeks with concurrent topical steroid, and most lesions disappeared completely with post inflammatory hyperpigmentation. No evidence of recurrence has been observed during 3 months of followup.

Keyword

Infliximab; Pustular psoriasis; TNF-alpha inhibitor

MeSH Terms

Adolescent
Antibodies, Monoclonal
Arthritis, Rheumatoid
Biopsy
Crohn Disease
Dermatitis
Follow-Up Studies
Humans
Hyperpigmentation
Psoriasis
Recurrence
Skin
Tumor Necrosis Factor-alpha
Infliximab
Antibodies, Monoclonal
Tumor Necrosis Factor-alpha
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr